Oral bioavailability of ATP after prolonged administration
about
Treatment with Oral ATP decreases alternating hemiplegia of childhood with de novo ATP1A3 MutationMultidrug Resistance-Associated Protein 2 Expression Is Upregulated by Adenosine 5'-Triphosphate in Colorectal Cancer Cells and Enhances Their Survival to Chemotherapeutic DrugsAdenosine-5'-triphosphate (ATP) supplementation improves low peak muscle torque and torque fatigue during repeated high intensity exercise sets.Twelve weeks supplementation with an extended-release caffeine and ATP-enhancing supplement may improve body composition without affecting hematology in resistance-trained men.Effects of oral adenosine-5'-triphosphate supplementation on athletic performance, skeletal muscle hypertrophy and recovery in resistance-trained men.Supplementation with a proprietary blend of ancient peat and apple extract may improve body composition without affecting hematology in resistance-trained men.The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders.P2X7 receptor as a novel drug delivery system to increase the entrance of hydrophilic drugs into cells during photodynamic therapy.Sublingual nucleotides and immune response to exercise.Sublingual nucleotides prolong run time to exhaustion in young physically active men.P2Y2 Receptor Functions in Cancer: A Perspective in the Context of Colorectal Cancer.Oral Adenosine-5'-triphosphate (ATP) Administration Increases Postexercise ATP Levels, Muscle Excitability, and Athletic Performance Following a Repeated Sprint Bout.
P2860
Q27301346-60F6EC44-2C60-497A-8F25-8BAC4B4C3DD6Q28547426-33D14DED-13F6-440D-B595-3179CF39B0EEQ36353941-E7441FB0-A8D3-4B99-9047-B7C3F762C247Q36991234-FCA693EC-5159-4D65-ABB2-CFA0B130EC9AQ37361183-70B1F564-39DC-42AD-924C-D9C96E424F18Q38421337-DD606FFD-75A9-4F67-9A6F-1A3F50585275Q38522643-8C9C1E40-7CC1-4261-B391-86E378E013A9Q38757891-D9D1E902-CF15-41AC-8F38-5148F5949CF6Q42028015-B3EDE53B-5B71-44B1-8529-1D5683F49C69Q42127003-246C8486-E1A8-49D4-ABB3-88B2AC2C51E0Q47943140-2570AF25-8455-4FB5-8729-90CBFA91C781Q50956412-2CB3B019-FED6-427E-A544-46A8696BBCA2
P2860
Oral bioavailability of ATP after prolonged administration
description
im Dezember 2010 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 06 December 2010
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2010
@uk
name
Oral bioavailability of ATP after prolonged administration
@en
Oral bioavailability of ATP after prolonged administration
@nl
type
label
Oral bioavailability of ATP after prolonged administration
@en
Oral bioavailability of ATP after prolonged administration
@nl
prefLabel
Oral bioavailability of ATP after prolonged administration
@en
Oral bioavailability of ATP after prolonged administration
@nl
P2093
P2860
P1476
Oral bioavailability of ATP after prolonged administration
@en
P2093
Chris Vervaet
Erik J C M Coolen
Otto Bekers
Pieter C Dagnelie
P2860
P304
P356
10.1017/S0007114510003570
P577
2010-12-06T00:00:00Z